Opioid mediation of the antiaversive and hyperalgesic actions of bradykinin injected into the dorsal periaqueductal gray of the rat.

Laboratory of Pharmacology, F.C.F.R.P., University of São Paulo, Brazil.
Physiology & Behavior (Impact Factor: 3.03). 10/1992; 52(3):405-10. DOI: 10.1016/0031-9384(92)90325-V
Source: PubMed

ABSTRACT Reported evidence indicates that the dorsal region of the periaqueductal gray matter (PAG) is involved in the modulation of both pain and aversion, and that opioid mechanisms, among others, participate in their modulation. Since many central actions of bradykinin (BK) have been shown to be similar to those of morphine, the present was undertaken to measure the effects of microinjection of BK into the PAG on the thresholds of aversive electrical stimulation of the same brain area and of dental pulp electrical stimulation. Bradykinin, injected into the dorsal PAG, induced a dose-dependent increase in the aversive threshold, an effect similar to that reported by others for morphine. Also, as reported for morphine, the antiaversive effect of BK was antagonized by naloxone injected intraperitoneally. Whereas subcutaneously administered morphine induced marked analgesia, intra-PAG administration of BK caused a small but significant hyperalgesia. Similarly, morphine injected into the dorsal PAG tended to cause hyperalgesia instead of analgesia. Furthermore, the hyperalgesic effect of BK also appears to involve opioid mechanisms since it was blocked by naloxone. As in previously reported studies, intracerebroventricularly injected BK raised the pain threshold. These results indicate that BK mobilizes opioid mechanisms in the dorsal PAG that inhibit aversion but not pain.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent years have seen significant advances in our understanding of the peripheral and spinal mechanisms through which prostaglandins contribute to nociceptive sensitization. By contrast, the possibility of a supraspinal contribution of these compounds to facilitated pain states has received relatively little attention. One possible mechanism through which prostaglandins could act supraspinally to facilitate nociception would be by recruitment of descending facilitation from brainstem pain-modulating systems. The rostral ventromedial medulla (RVM) is now known to contribute to enhanced responding in a variety of inflammatory and nerve injury models. Its major supraspinal input, the midbrain periaqueductal gray (PAG), expresses prostanoid receptors and synthetic enzymes. The aim of the present study was to determine whether direct application of prostaglandin E2 (PGE2) within the ventrolateral PAG is sufficient to produce hyperalgesia, and whether any hyperalgesia could be mediated by recruiting nociceptive modulating neurons in the RVM. We determined the effects of focal application of PGE2 in the PAG on paw withdrawal latency and activity of identified nociceptive modulating neurons in the RVM of lightly anesthetized rats. Microinjection of PGE2 (50 fg in 200 nl) into the PAG produced a significant decrease in paw withdrawal latency. The PGE2 microinjection activated on-cells, RVM neurons thought to facilitate nociception, and suppressed the firing of off-cells, RVM neurons believed to have an inhibitory effect on nociception. These data demonstrate a prostaglandin-sensitive descending facilitation from the PAG, and suggest that this is mediated by on- and off-cells in the RVM.
    Pain 05/2004; DOI:10.1016/S0304-3959(04)00218-0 · 5.84 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: The effect of small and high doses of intracerebroventricularly (icv) applied bradykinin (BK) on nociception produced by mechanical stimuli and the participation of B1 and B2 receptors in this nociception were investigated in rats. Results: BK at the lowest dose (0.06 μg) produced hyperalgesia whereas at the higher doses (6 and 12 μg) antinociception. This effect was abolished by B1 or B2 receptor antagonists, des-Arg(10)-HOE140 and HOE140 (1 pmol icv), respectively. Conclusion: Depending on the dose used, BK produces pro- or anti-nociceptive action. Both B1 and B2 receptors are involved in the action of icv applied BK.
    Pharmacological reports: PR 07/2013; 65(4):1006-11. DOI:10.1016/S1734-1140(13)71082-X · 2.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The dorsal periaqueductal gray matter (DPAG), superior and inferior colliculus have been implicated in the control of defense reactions in the midbrain. Electrical and chemical stimulation of these structures induces escape behavior, usually accompanied by autonomic responses and antinociception. GABA, 5-HT, opioids, excitatory amino acids and neuropeptides have been postulated to participate in the organization of such defensive reactions in the midbrain tectum. However, little attention has been given to a possible involvement of histamine in the generation of such behavior. To examine this issue in the present study, we assessed the effects of injections into the midbrain tectum of histamine and the H1 and H2 receptor antagonists, chlorpheniramine and ranitidine on the behavioral manifestations of the defense reaction. The effects of these drugs were also examined on antinociception, which has been considered to be an inherent component of the defense reaction. Thus, the animals were submitted to an open field test and after 30 min, antinociceptive behavior was measured with the aid of the tail-flick test. The results show that histamine reduced exploratory activity without causing motor deficit, as evaluated by the rotarod test. Ranitidine led to a dose-dependent behavioral activation, with clear signs of fear, whereas no apparent effect was observed following injections of chlorpheniramine. Antinociception always followed the escape reaction induced by the H2 receptor blocker ranitidine. The present results suggest that H2 receptors may be involved in the control of escape behavior and antinociception following activation of the neural substrates of fear in the midbrain tectum.
    Behavioural Brain Research 10/2001; 124(2):167-175. DOI:10.1016/S0166-4328(01)00228-5 · 3.39 Impact Factor